| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A historical victory for Europe?
|
|
|
|
12 |
8 |
p. 1028-1029
|
artikel
|
| 2 |
Are European cancer patients getting a fair deal?
|
McVie, J.G.
|
|
|
12 |
8 |
p. 1033-1035
|
artikel
|
| 3 |
Are European cancer patients getting a fair deal?
|
J. G. McVie
|
|
2001
|
12 |
8 |
p. 1033-1035
3 p.
|
artikel
|
| 4 |
Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor
|
Rick, O.
|
|
|
12 |
8 |
p. 1151-1155
|
artikel
|
| 5 |
Assessment of amifostine as protection from chemotherapy-inducedtoxicities after conventional-dose and high-dose chemotherapy in patients withgerm cell tumor
|
O. Rick
|
|
2001
|
12 |
8 |
p. 1151-1155
5 p.
|
artikel
|
| 6 |
Aventis Pharmaceuticals
|
|
|
|
12 |
8 |
p. 1182
|
artikel
|
| 7 |
Bones to chew for the stock market?
|
|
|
|
12 |
8 |
p. 1028
|
artikel
|
| 8 |
Book review
|
Cerundolo, V.
|
|
|
12 |
8 |
p. 1182
|
artikel
|
| 9 |
Book review
|
Starobinski, M.
|
|
|
12 |
8 |
p. 1032
|
artikel
|
| 10 |
Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
|
Gianni, L.
|
|
|
12 |
8 |
p. 1065-1071
|
artikel
|
| 11 |
Cardiac function following combination therapy with paclitaxel anddoxorubicin: An analysis of 657 women with advanced breast cancer
|
L. Gianni
|
|
2001
|
12 |
8 |
p. 1067-1073
7 p.
|
artikel
|
| 12 |
Chemoradiotherapy for rectal cancer – is there an optimal combination?
|
Glimelius, B.
|
|
|
12 |
8 |
p. 1039-1045
|
artikel
|
| 13 |
Chemoradiotherapy for rectal cancer is there an optimalcombination?
|
B. Glimelius
|
|
2001
|
12 |
8 |
p. 1039-1045
7 p.
|
artikel
|
| 14 |
Childhood leiomyosarcoma: A report from the Soft Tissue Sarcoma Italian Cooperative Group
|
Ferrari, A.
|
|
|
12 |
8 |
p. 1163-1168
|
artikel
|
| 15 |
Childhood leiomyosarcoma: A report from the Soft Tissue Sarcoma ItalianCooperative Group
|
A. Ferrari
|
|
2001
|
12 |
8 |
p. 1163-1168
6 p.
|
artikel
|
| 16 |
Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines
|
Martí, J.L.
|
|
|
12 |
8 |
p. 1061-1065
|
artikel
|
| 17 |
Combination chemotherapy with docetaxel plus vinorelbine in metastaticbreast cancer patients with prior exposure to anthracyclines
|
J. L. Martí
|
|
2001
|
12 |
8 |
p. 1061-1065
5 p.
|
artikel
|
| 18 |
Contents of the next issue
|
|
|
|
12 |
8 |
p. iv
|
artikel
|
| 19 |
Copyright
|
|
|
|
12 |
8 |
p. ii
|
artikel
|
| 20 |
Correlation between c-erbB-4 receptor expression and response to gemcitabine–cisplatin chemotherapy in non-small-cell lung cancer
|
Merimsky, O.
|
|
|
12 |
8 |
p. 1127-1131
|
artikel
|
| 21 |
Correlation between c-erbB-4 receptor expression and response togemcitabinecisplatin chemotherapy in non-small-cell lung cancer
|
O. Merimsky
|
|
2001
|
12 |
8 |
p. 1127-1131
5 p.
|
artikel
|
| 22 |
D. B. Lowrie & R. G. Whalen (eds.), DNA Vaccines: Methods and Protocols
|
V. Cerundolo
|
|
2001
|
12 |
8 |
p. 1182-1182
1 p.
|
artikel
|
| 23 |
Doxorubicin-based chemotherapy in the elderly
|
Sulkes, A.
|
|
|
12 |
8 |
p. 1180-1181
|
artikel
|
| 24 |
Doxorubicin-based chemotherapy in the elderly
|
A. Sulkes
|
|
2001
|
12 |
8 |
p. 1180-1181
2 p.
|
artikel
|
| 25 |
Editorial Board
|
|
|
|
12 |
8 |
p. iii
|
artikel
|
| 26 |
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer
|
|
|
|
12 |
8 |
p. 1053-1054
|
artikel
|
| 27 |
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatmentand follow-up of colon cancer
|
|
|
2001
|
12 |
8 |
p. 1053-1054
2 p.
|
artikel
|
| 28 |
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer
|
|
|
|
12 |
8 |
p. 1047-1048
|
artikel
|
| 29 |
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatmentand follow-up of primary breast cancer
|
|
|
2001
|
12 |
8 |
p. 1047-1048
2 p.
|
artikel
|
| 30 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer
|
|
|
|
12 |
8 |
p. 1055
|
artikel
|
| 31 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of advanced colorectal cancer
|
|
|
2001
|
12 |
8 |
p. 1055-1055
1 p.
|
artikel
|
| 32 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)
|
|
|
|
12 |
8 |
p. 1057-1058
|
artikel
|
| 33 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of cancers of unknown primary site (CUP)
|
|
|
2001
|
12 |
8 |
p. 1057-1058
2 p.
|
artikel
|
| 34 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)
|
|
|
|
12 |
8 |
p. 1049-1050
|
artikel
|
| 35 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of non-small-cell lung cancer (NSCLC)
|
|
|
2001
|
12 |
8 |
p. 1049-1050
2 p.
|
artikel
|
| 36 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)
|
|
|
|
12 |
8 |
p. 1051-1052
|
artikel
|
| 37 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment andfollow-up of small-cell lung cancer (SCLC)
|
|
|
2001
|
12 |
8 |
p. 1051-1052
2 p.
|
artikel
|
| 38 |
ESMO Minimum Clinical Recommendations – the beginning of a process
|
Stahel, R.
|
|
|
12 |
8 |
p. 1037-1038
|
artikel
|
| 39 |
ESMO Minimum Clinical Recommendations the beginning of aprocess
|
R. Stahel
|
|
2001
|
12 |
8 |
p. 1037-1038
2 p.
|
artikel
|
| 40 |
ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)
|
|
|
|
12 |
8 |
p. 1059-1060
|
artikel
|
| 41 |
ESMO Recommendations for prophylaxis of chemotherapy-induced nausea andvomiting (NV)
|
|
|
2001
|
12 |
8 |
p. 1059-1060
2 p.
|
artikel
|
| 42 |
Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma
|
Saijo, Y.
|
|
|
12 |
8 |
p. 1121-1125
|
artikel
|
| 43 |
Expression of nucleolar protein p120 predicts poor prognosis in patientswith stage I lung adenocarcinoma
|
Y. Saijo
|
|
2001
|
12 |
8 |
p. 1121-1125
5 p.
|
artikel
|
| 44 |
Generics or original agents? But which originals?
|
|
|
|
12 |
8 |
p. 1027
|
artikel
|
| 45 |
HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
|
Di Leo, A.
|
|
|
12 |
8 |
p. 1081-1089
|
artikel
|
| 46 |
HER-2 and topo-isomerase II as predictive markers in a populationof node-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide
|
A. Di Leo
|
|
2001
|
12 |
8 |
p. 1081-1089
9 p.
|
artikel
|
| 47 |
How long will we be able to afford increasing costs of healthcare? Or are they truly increasing?
|
|
|
|
12 |
8 |
p. 1027
|
artikel
|
| 48 |
How long will we be able to afford increasing costs of healthcare? Or are they truly increasing?Generics or original agents? But which originals?The risks of natural remedies.The Peto brothers strike again: On smoking and obesity.Oxigene needs some oxygen.Bones to chew for the stock market?Talis pater, talis filia.A historical victory for Europe?Resistance to STI-571.Perhaps not everyone knows that...
|
|
|
2001
|
12 |
8 |
p. 1027-1031
5 p.
|
artikel
|
| 49 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
|
Venturini, M.
|
|
|
12 |
8 |
p. 1097-1106
|
artikel
|
| 50 |
Identification of the highest dose of docetaxel associable with activedoses of epirubicin. Results from a dose-finding study in advanced breastcancer patients
|
M. Venturini
|
|
2001
|
12 |
8 |
p. 1097-1106
10 p.
|
artikel
|
| 51 |
In this issue
|
|
|
|
12 |
8 |
p. iv
|
artikel
|
| 52 |
Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases
|
Fakih, M.
|
|
|
12 |
8 |
p. 1173-1177
|
artikel
|
| 53 |
Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma:A series of six cases
|
M. Fakih
|
|
2001
|
12 |
8 |
p. 1173-1177
5 p.
|
artikel
|
| 54 |
Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy
|
Pergolizzi, S.
|
|
|
12 |
8 |
p. 1091-1095
|
artikel
|
| 55 |
Ipsilateral supraclavicular lymph nodes metastases from breast cancer asonly site of disseminated disease. Chemotherapy alone vs. inductionchemotherapy to radical radiation therapy
|
S. Pergolizzi
|
|
2001
|
12 |
8 |
p. 1091-1095
5 p.
|
artikel
|
| 56 |
J. Rowe, H. Lazarus & A. Carella (eds), Handbook of Bone MarrowTransplantation
|
M. Starobinski
|
|
2001
|
12 |
8 |
p. 1032-1032
1 p.
|
artikel
|
| 57 |
Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer
|
Gianni, L.
|
|
|
12 |
8 |
p. 1179-1180
|
artikel
|
| 58 |
Meta-analyses of randomized trials of adjuvant chemotherapy ingastric cancer
|
L. Gianni
|
|
2001
|
12 |
8 |
p. 1179-1180
2 p.
|
artikel
|
| 59 |
Oxigene needs some oxygen
|
|
|
|
12 |
8 |
p. 1028
|
artikel
|
| 60 |
Perhaps not everyone knows that…
|
|
|
|
12 |
8 |
p. 1029-1031
|
artikel
|
| 61 |
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
|
Ramanathan, R.K.
|
|
|
12 |
8 |
p. 1139-1143
|
artikel
|
| 62 |
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cellcarcinoma. Study of the Eastern Cooperative Oncology Group-E6282
|
R. K. Ramanathan
|
|
2001
|
12 |
8 |
p. 1139-1143
5 p.
|
artikel
|
| 63 |
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
|
Yamada, Y.
|
|
|
12 |
8 |
p. 1133-1137
|
artikel
|
| 64 |
Phase II trial of paclitaxel by three-hour infusion for advanced gastriccancer with short premedication for prophylaxis against paclitaxel-associatedhypersensitivity reactions
|
Y. Yamada
|
|
2001
|
12 |
8 |
p. 1133-1137
5 p.
|
artikel
|
| 65 |
Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute
|
Ferrari, S.
|
|
|
12 |
8 |
p. 1145-1150
|
artikel
|
| 66 |
Predictive factors of disease-free survival for non-metastaticosteosarcoma of the extremity: An analysis of 300 patients treated at theRizzoli Institute
|
S. Ferrari
|
|
2001
|
12 |
8 |
p. 1145-1150
6 p.
|
artikel
|
| 67 |
Resistance to STI-571
|
|
|
|
12 |
8 |
p. 1029
|
artikel
|
| 68 |
Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: A simulation study
|
Jacobs, H.J.M.
|
|
|
12 |
8 |
p. 1107-1113
|
artikel
|
| 69 |
Routine follow-up examinations in breast cancer patients have minimalimpact on life expectancy: A simulation study
|
H. J. M. Jacobs
|
|
2001
|
12 |
8 |
p. 1107-1113
7 p.
|
artikel
|
| 70 |
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
|
du Bois, A.
|
|
|
12 |
8 |
p. 1115-1120
|
artikel
|
| 71 |
Second-line carboplatin and gemcitabine in platinum sensitive ovariancancer a dose-finding study by the ArbeitsgemeinschaftGynäkologische Onkologie (AGO) Ovarian Cancer Study Group
|
A. du Bois
|
|
2001
|
12 |
8 |
p. 1115-1120
6 p.
|
artikel
|
| 72 |
Table of Contents
|
|
|
|
12 |
8 |
p. i-ii
|
artikel
|
| 73 |
Talis pater, talis filia
|
|
|
|
12 |
8 |
p. 1028
|
artikel
|
| 74 |
Targeted intra-operative radiotherapy (Targit): An innovative method of treatment for early breast cancer
|
Vaidya, J.S.
|
|
|
12 |
8 |
p. 1075-1080
|
artikel
|
| 75 |
Targeted intra-operative radiotherapy(Targit): An innovative method of treatment for early breastcancer
|
J. S. Vaidya
|
|
2001
|
12 |
8 |
p. 1075-1080
6 p.
|
artikel
|
| 76 |
The above letter was referred to the authors, who respond as follows:
|
Ibrahim, N.K.
|
|
|
12 |
8 |
p. 1181
|
artikel
|
| 77 |
The above letter was referred to the authors, who respond as follows:
|
Floriani, I.
|
|
|
12 |
8 |
p. 1180
|
artikel
|
| 78 |
The above letter was referred to the authors, who respond asfollows
|
I. Floriani
|
|
2001
|
12 |
8 |
p. 1180-1180
1 p.
|
artikel
|
| 79 |
The above letter was referred to the authors, who respond asfollows
|
N. K. Ibrahim
|
|
2001
|
12 |
8 |
p. 1181-1181
1 p.
|
artikel
|
| 80 |
The Peto brothers strike again: On smoking and obesity
|
|
|
|
12 |
8 |
p. 1027-1028
|
artikel
|
| 81 |
The risks of natural remedies
|
|
|
|
12 |
8 |
p. 1027
|
artikel
|
| 82 |
Transformation of Hodgkin’s disease to high-grade B-cell lymphoma: Remission after Rituximab monotherapy
|
Kirchner, E.M.
|
|
|
12 |
8 |
p. 1169-1171
|
artikel
|
| 83 |
Transformation of Hodgkins disease to high-grade B-cell lymphoma:Remission after Rituximab monotherapy
|
E. M. Kirchner
|
|
2001
|
12 |
8 |
p. 1169-1171
3 p.
|
artikel
|
| 84 |
Undifferentiated nasopharyngeal carcinoma in children and adolescents: Comparison between staging systems
|
Casanova, M.
|
|
|
12 |
8 |
p. 1157-1162
|
artikel
|
| 85 |
Undifferentiated nasopharyngeal carcinoma in children and adolescents:Comparison between staging systems
|
M. Casanova
|
|
2001
|
12 |
8 |
p. 1157-1162
6 p.
|
artikel
|
Tijdschrift beschrijving